Abstract
At its June 2012 meeting, the Advisory Committee on Immunization Practices (ACIP) voted to recommend pneumococcal 13-valent protein conjugate vaccine (PCV13; Prevnar-13–Pfizer) in adults 19 years or older with specific immunocompromising conditions. The recommendations were posted on October 12, 2012. 1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
